Dare Bioscience, Inc. (DARE) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

financial results and to provide the business update. This call is being recorded. My name is Jericho and I will be your operator today. With us today from DARE are Sabrina Martucci-Johnson, President and Chief Executive Officer, and Mardi Herring-Layton, Chief Accounting Officer. Ms. Herring-Layton, please proceed. Good afternoon and welcome to the DARE Bioscience Financial Results and Business Update call for the quarter ended September 30th, 2025. Today we will review our financial results, provide updates on our clinical pipeline, and discuss the continued execution of our expanded business strategy. That strategy includes a dual path approach, commercializing proprietary formulations through 503 compounding while pursuing FDA approval, and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our Form 10-Q for the quarter ended September 30, 19, sorry, 2025. which was filed today in our ...